© 2020 MJH Life Sciences and . All rights reserved.
STAMPEDE: Front-Line Docetaxel Prolongs Survival in Metastatic Prostate Cancer
June 4, 2015
In this video, Dr. Nicholas David James discusses the results of the STAMPEDE trial, which tested front-line docetaxel combined with hormonal therapy in patients with advanced, hormone-naive prostate cancer.
In this video, Dr. Nicholas David James discusses the results of the STAMPEDE trial, which tested front-line docetaxel combined with hormonal therapy in patients with advanced, hormone-naive prostate cancer.